Taking a multidisciplinary approach to allergy and immunology

Inmunotek brings a range of skills and specialties together to create vaccine-based approaches for the treatment of allergy, recurrent infections and other immune-related diseases.

Like Comment

Download the Full PDF

Based in Madrid, Inmunotek’s focus is on the develop­ment, manufacture and marketing of products in the field of allergy and immunology. Inmunotek’s mar­keted product portfolio includes immunotherapies, diagnostics and medical devices.

While the company is based in Spain, Inmunotek has sales offices and subsidiaries in Portugal and in the Spanish-speaking countries of Latin America, and has distribution and contract manufacturing partner­ships around the world.

The company has had a sustained revenue growth rate of around 20% over the past 10 years and was in the Financial Times’ top 1000 of Europe’s fastest grow­ing companies in 2017. The company’s R&D program includes allergy vaccines, mucosal vaccines to prevent infections, vaccine adjuvants and antitumor vaccines.

Building a new concept in vaccines

Vaccines in development at Inmunotek include a pipeline of polybacterial whole-cell vaccines. These target the mucosal innate immune system and aim to trigger a broad anti-infective response.

“We are very excited about our development of a pipeline of bacterial vaccines for active mucosal immunotherapy to prevent recurrent infectious dis­eases in adults and children,” said Miguel Casanovas, medical director at Inmunotek. “We describe these as ‘trained immunity’ vaccines,” said Casanovas, “and we think the concept could be used to create a platform with potential against a wide range of infections.”

Vaccines usually depend on adaptive immunity, with the induction of T and B memory cells that are triggered the following time the pathogen is encoun­tered. The innate immune system can also ‘remember’ pathogens, in what has been described as ‘trained immunity’ (Fig. 1). This supports the development of longer-lasting immunity against both vaccine-related and unrelated bystander pathogens.

Fig. 1 | Trained immunity-based vaccines. DC, dendritic cells; Mo, monocytes; PRR, pattern recognition receptors; Th, T helper cell; Th0, naïve T cells; TIV, trained immunity vaccine.

Inmunotek’s mucosal vaccine pipeline

Inmunotek’s bacterial vaccines use the ‘trained immu­nity’ effect, and are made up of mixtures of inactivated whole-cell bacteria that are administered under the tongue. MV130 (Bactek) is in development to prevent recurrent respiratory tract infections, and MV140 (Uromune) targets recurrent urinary tract infections.

One of the advantages of using mucosal rather than parenteral vaccines for infections in the respi­ratory and urinary tract is that they stimulate the mucosal immune system, which is the primary first defense against these types of infection.

“In preclinical studies, MV130 and MV140 show a broad activity against both related and unrelated antigens, triggering immune responses to patho­gens not in the bacterial vaccine preparation as well,” said Casanovas.

MV130 has completed a phase 3, double-blind, placebo-controlled clinical trial for the prevention of recurrent wheezing in children, a condition mainly caused by viral infections, such as rhinoviruses. There are no specific vaccines currently available for these viral infections.

“The recurrent wheezing study showed outstand­ing positive results,” said Casanovas.

The same vaccine is currently in a double-blind, placebo-controlled phase 3 efficacy and safety study in patients with chronic obstructive pulmo­nary disease (COPD), with an aim to reduce the number of COPD exacerbations. This study is due to be completed in 2019.

Also due to be completed in 2019, MV140 is in a double-blind, placebo-controlled phase 3 safety and efficacy study to assess its ability to reduce the recur­rence of cystitis.

“Cystitis can be caused by uropathogenic bacteria and requires long periods of treatment with anti- biotics. Pilot studies with MV140 have shown that this preparation prevents recurrence of infection with bacteria, including those not in the vaccine, show­ing a protective effect that goes beyond the bacterial composition of MV140,” said Casanovas.

Inmunotek believes that broadly active vaccines that target trained immunity may be a valuable alternative when conventional vaccines are not avail­able or when a number of different microorganisms cause co-infections.


Miguel Casanovas, Medical Director
Madrid, Spain
Tel: +34 912 908 942
Email: mcasanovas@inmunotek.com
Website: www.inmunotek.com

Go to the profile of Inmunotek


Pharmaceutical company based in Madrid, Spain. Founded in 1992, Inmunotek researches, develops, manufactures and markets diagnostics and therapeutics (vaccines) in the field of allergy and immunology. It has two GMP-facilities and R&D laboratories in Spain. Inmunotek employs 225 persons (2018), invests over 10% of its turnover in R&D projects and is included among the faster-growing companies in Europe. Inmunotek’s main interest is focused to therapeutic vaccines for allergy, recurrent infectious diseases and cancer. In the field of allergy, major developments include novel allergy vaccines targeting dendritic cells for both human and veterinary medicines. In the field of recurrent infections, major developments include mucosal (sublingual) bacterial vaccines targeting innate immunity for upper respiratory and urological (cystitis) infections. Cancer research is focused to the development of novel carbohydrate-based tumor vaccines. Inmunotek’s products are distributed worldwide in more than 50 countries.

No comments yet.